www.elderindia.

com

CHYMORAL PLUS
Deleted: ¶
COMPOSITION:

Trypsin: Chymotrypsin (6:1) 50,000 A.U.(Enteric coated)
Diclofenac potassium (immediate release) 50 mg

DESCRIPTION
CHYMORAL PLUS contains proteolytic enzymes Trypsin & Chymotrypsin.
These have been used widely, with significant clinical success in the
¶
management of minor trauma & wound healing and in reducing the healing
Formatted: Indent: Left: 0"
time.

Diclofenac is the time-tested analgesic belonging to the group of Nonsteroidal

anti-inflammatory drugs.

HIGHLIGHTS

Reduces - oedema, haematoma and inflammation

Restores microcirculation

Enhances phagocytosis

Minimises necrosis and scar formation

Enhances penetration of co-prescribed antibiotics

Shortens recovery time by 50%

Diclofenac provides the early analgesia required during the phase of

inflammation.

CLINICAL PHARMACOLOGY
When CHYMORAL PLUS 50,000 A.U. (four times daily) is administered on
an empty stomach, the enteric coated Trypsin and Chymotrypsin are released
and absorbed in the small intestine.

Updated as on 19 SEPTEMBER 2005

 www.elderindia.com

Fibrinolytic action
When fibrin clots have stopped bleeding, body’s own fibrinolytic agent –
plasmin breaks the fibrin barrier. Liver, in response to trauma, releases APR’s
(Acute Phase Reactants) that inhibit Plasmin (and its fibrinolytic action).
Breaking of fibrin barrier improves and restores circulation, resolving oedema,
hematoma and pain, promoting phagocytosis to remove the debris and
accelerate recovery. This is the action of CHYMORALPLUS.

Studies:
1. Action of trypsin:chymotrypsin (Chymoral Plus) preparation on acute
phase proteins following burn injury in humans. B. Latha, M.
Ramakrishnan, V.Jayaraman & MaryBabu. Burns. V. 23, S.No.1, pp. S3-
S7, 1997.
2. Serum enzymatic changes modulated using trypsin:chymotrypsin
preparation during burn wounds in humans. B.Latha, M.Ramakrishnan,
V.Jayaraman & MaryBabu Burns. V.7/8, pp. 560-564, 1997.
3. Efficacy of trypsin:chymotrypsin preparation in the reduction of oxidative
damage during burn injury in humans. B.Latha, M.Ramakrishnan,
V.Jayaraman & MaryBabu. Burns. V.24, pp.532-538, 1998.
4. Analysis of an open multicentric study of the efficacy, safety and
tolerability of Chymoral Forte® in resolving signs and symptoms of
inflammation in patients with traumatic injuries. Apsangikar P,* Naik M,
Tike C. Hospital Today Vol X No. 1, January-March 2005.

Diclofenac belongs to the NSAIDs group and causes pain relief and relieves
of inflammation by blocking the Cyclo-oxygenase enzyme in the inflammatory
cascade.
Diclofenac potassium is the pharmacokinetically preferred salt of diclofenac.

INDICATIONS AND USAGE

In trauma and inflammation with Oedema & Haematoma:

Updated as on 19 SEPTEMBER 2005

 www.elderindia.com

Surgery: post-operative wounds, inflammation due to stitches

Gynaecology: PID, caesarian section, episiotomy, hysterectomy, D & C
etc.

Dentistry: Tooth extraction, periapical abscess, maxilofacial surgery

Orthopaedics: post-traumatic oedema, soft tissue injury, fractures and
dislocations, sports injury, sprains and strains.

CONTRAINDICATIONS
Hypersensitivity to the active ingredients, presence of peptic or duodenal ulcer.

PRECAUTIONS
In patients with a history of sensitivity to enzymes or other drugs, caution should
be exercised. Used with caution in patients with acid peptic disease.
Safety has not been established in pregnancy and children.

ADVERSE REACTIONS
Generally, CHYMORAL PLUS is well tolerated. However certain effects can be
seen Occasional gastric disturbance may occur.

Diclofenac commonly can cause nausea, gastritis, heartburn and rarely

nephrotoxicity.

DOSAGE AND ADMINISTRATION

1 tablet 2-3 times a day, half an hour before meals. The tablet must be
swallowed whole to preserve the enteric coating. Treatment should begin as
soon as possible after injury occurs.

PRESENTATION
CHYMORAL PLUS is available in a strip of 10 tablets.

Updated as on 19 SEPTEMBER 2005